You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses and Publications

Congress Materials

Access English-language abstracts, posters, and presentations presented at the following congresses

October 2024

International Society of Paediatric Oncology (SIOP)

October 2024

German, Austrian, and Swiss Societies for Hematology and Oncology (DGHO)

German, Austrian, and Swiss Societies for Hematology and Oncology (DGHO)

October 2024 (Basel, Switzerland)

Abstracts

2 years of zanubrutinib in Germany: a retrospective cohort study Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL with del(17p) and/or TP53: preliminary results from SEQUOIA arm D Combination treatment (tx) with novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) and zanubrutinib (zanu) induces high rate of complete remission in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Outcomes ≥1 year after transitioning from treatment with ibrutinib (ibru) in the ASPEN study to zanubrutinib (zanu) Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (pts) with relapsed or refractory (R/R) indolent NHL: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 Inhibitor, in treatment-naive (TN) patients with acute myeloid leukemia (AML) Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients (pts) with relapsed/refractory (R/R) acute myeloid leukemia (AML) Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) in combination with zanubrutinib (zanu) for relapsed/refractory (R/R) CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (sonro; BGB-11417) for relapsed/refractory (R/R) Waldenström macroglobulinemia (WM) Sonrotoclax (sonro; BGB-11417) + dexamethasone (dex) is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma (MM) harboring t(11;14)
September 2024

European Research Initiative on CLL (ERIC CLL)

September 2024

Korean Society of Medical Oncology (KSMO)

September 2024

International Myeloma Society Meeting (IMS)

September 2024

Chinese Society of Clinical Oncology (CSCO)

Chinese Society of Clinical Oncology (CSCO)

September 2024 (Xiamen, China)

Abstracts

A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: Preliminary data A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma (NHL) or Waldenström macroglobulinemia (WM): Preliminary data A phase 2 study of sitravatinib in combination with tislelizumab versus chemotherapy in patients with locally advanced unresectable or metastatic esophageal squamous cell carcinoma that progressed on or after anti–PD-1/anti–PD-L1 antibody therapy CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naive CLL China subgroup results of the phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC) Combination treatment with novel BCL-2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Efficacy and safety of tislelizumab + chemotherapy vs placebo + chemotherapy in HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 study Chinese subgroup analysis Extended follow-up of ALPINE randomized phase 3 study confirms sustained superior progression-free survival of zanubrutinib versus ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Impact of first-line treatment with tislelizumab on health-related quality of life in Chinese patients with unresectable hepatocellular carcinoma Improved efficacy and safety of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in China: a subgroup of ALPINE Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory CLL/SLL: results from the phase 1 BGB-16673-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 1 BGB-16673-101 study Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Preliminary safety and antileukemic activity of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia Results from the phase 1 study of the novel BCL2 inhibitor sonrotoclax in combination with zanubrutinib for relapsed/refractory CLL/SLL show deep and durable responses Safety and efficacy results of a phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory Waldenström macroglobulinemia Sonrotoclax plus dexamethasone is tolerable and demonstrates antimyeloma activity in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14) Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Updated results from a Phase Ib/II study Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): final analysis of ALPINE randomized phase 3 study Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQOL)

Most Recent Publications

Banner image with blue and red molecule Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

Search Publications and Congress Materials

This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.

BeiGene, Ltd. maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeiGene’s written permission.  
 
This is an online medical resource for scientific and clinical information. BeiGene makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.